About Anpac Bio

Decades of research by the world’s most respected cancer scientists and physicians consistently reveal one conclusion:

Most people can survive cancer if the disease is caught early.

This fact led Anpac Bio’s Co-Founders, Dr. Chris Yu and Dr. Herbert Yu, to ask the question that ultimately launched the company:

“What if we could detect cancer before tumors start?”

Achieving that goal became the Anpac Bio’s Co-Founders’ quest. They began breaking the problem apart—drawing on expertise in:

    • Cancer research
    • Bio-chemistry
    • Chemistry
    • Nano-technology
    • Surface science
    • Material science
    • Detection
    • Physics
    • Engineering and manufacturing

Together they founded Anpac Bio-Medical Science Co., Ltd. in 2008, bringing together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their unique, cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve vastly superior early cancer screening and detection technology.

Visionary Science
Anpac Bio’s patented Cancer Differentiation Analysis (CDA) technology reinvents cancer screening and early detection. CDA “Blood Biopsy” identifies over 26+ cancers earlier and more accurately than traditional technologies, with greater sensitivity and specificity, fewer “false positives,” at a cost that is substantially less than traditional tests—all while producing no side-effects in patients.
Anpac Bio has filed over 200 patent applications globally with ~107 patent applications issued.

Learn More

Game Changing
CDA technology was called “game changing” at the Nobel Prize Laureate Summit on Biomedical Science.